↓ Skip to main content

Dove Medical Press

Estimating health-state utility values for patients with recurrent ovarian cancer using Functional Assessment of Cancer Therapy – General mapping algorithms

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, November 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (69th percentile)
  • Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

policy
1 policy source
twitter
3 X users

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
33 Mendeley
Title
Estimating health-state utility values for patients with recurrent ovarian cancer using Functional Assessment of Cancer Therapy – General mapping algorithms
Published in
ClinicoEconomics and Outcomes Research: CEOR, November 2015
DOI 10.2147/ceor.s92078
Pubmed ID
Authors

Robert Hettle, John Borrill, Gaurav Suri, Jerome Wulff

Abstract

In the absence of EuroQol 5D data, mapping algorithms can be used to predict health-state utility values (HSUVs) for use in economic evaluation. In a placebo-controlled Phase II study of olaparib maintenance therapy (NCT00753545), health-related quality of life was measured using the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) questionnaire. Our objective was to generate HSUVs from the FACT-O data using published mapping algorithms. Algorithms were identified from a review of the literature. Goodness-of-fit and patient characteristics were compared to select the best-performing algorithm, and this was used to generate base-case HSUVs for the intention-to-treat population of the olaparib study and for patients with breast cancer antigen mutations. Four FACT - General (the core component of FACT-O) mapping algorithms were identified and compared. Under the preferred algorithm, treatment-related adverse events had no statistically significant effect on HSU (P>0.05). Discontinuation of the study treatment and breast cancer antigen mutation status were both associated with a reduction in HSUVs (-0.06, P=0.0009; and -0.03, P=0.0511, respectively). The mean HSUV recorded at assessment visits was 0.786. FACT - General mapping generated credible HSUVs for an economic evaluation of olaparib. As reported in other studies, different algorithms may produce significantly different estimates of HSUV. For this reason, it is important to test whether the choice of a specific algorithm changes the conclusions of an economic evaluation.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 3%
Unknown 32 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 21%
Other 4 12%
Student > Ph. D. Student 4 12%
Student > Doctoral Student 2 6%
Student > Postgraduate 2 6%
Other 4 12%
Unknown 10 30%
Readers by discipline Count As %
Medicine and Dentistry 8 24%
Economics, Econometrics and Finance 4 12%
Pharmacology, Toxicology and Pharmaceutical Science 3 9%
Biochemistry, Genetics and Molecular Biology 2 6%
Agricultural and Biological Sciences 2 6%
Other 3 9%
Unknown 11 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 March 2021.
All research outputs
#7,430,186
of 25,584,565 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#150
of 524 outputs
Outputs of similar age
#86,073
of 295,303 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#4
of 17 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 524 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 295,303 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.